---
title: "Outlook Therapeutics FY26 Q3 net loss narrows to $20.32 million; revenue drops to $9,000"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295925657.md"
description: "Outlook Therapeutics reported a narrowed GAAP net loss of $20.3 million for Q3 FY2026, with revenue dropping significantly to $9,000 from $1.51 million the previous year. While operating losses decreased, adjusted non-GAAP net loss improved to $10.9 million. The company plans to launch FDA-approved LYTENAVA in the U.S. by late 2026, targeting annual sales exceeding $500 million by 2030."
datetime: "2026-08-14T11:15:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295925657.md)
  - [en](https://longbridge.com/en/news/295925657.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295925657.md)
---

# Outlook Therapeutics FY26 Q3 net loss narrows to $20.32 million; revenue drops to $9,000

-   Outlook Therapeutics posted a GAAP net loss attributable to common stockholders of USD 20.3 million, or USD 0.15 a share, in Q3 FY2026. \* Loss per share narrowed from USD 0.55 a year earlier, reflecting a larger share base. \* Revenue fell to USD 9,000 from USD 1.51 million a year earlier, while operating loss narrowed to USD 10.81 million from USD 15.75 million. \* Adjusted net loss attributable to common stockholders (non-GAAP) improved to USD 10.9 million, or USD 0.09 a share, from USD 15.8 million. \* Management plans a U.S. launch of FDA-approved LYTENAVA by end-2026, targeting potential annual U.S. sales above USD 500 million by 2030. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140715PRIMZONEFULLFEED9810131) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [OTLK.US](https://longbridge.com/en/quote/OTLK.US.md)

## Related News & Research

- [Outlook Therapeutics (OTLK) Fiscal Q3 2026 Earnings Call: LYTENAVA Launch and Revenue Guidance](https://longbridge.com/en/news/295969487.md)
- [Outlook Therapeutics Q3 net loss narrows slightly as costs drop](https://longbridge.com/en/news/295926842.md)
- [OTLK: FDA approval and launch plans for LYTENAVA drive growth prospects amid improved financials](https://longbridge.com/en/news/295929118.md)
- [Outlook Therapeutics launches public offering with accompanying stock purchase warrants](https://longbridge.com/en/news/295702300.md)
- [Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9](https://longbridge.com/en/news/295983837.md)